Quarterly report pursuant to Section 13 or 15(d)

CONSOLIDATED CONDENSED STATEMENTS OF OPERATIONS (Unaudited)

v2.4.0.8
CONSOLIDATED CONDENSED STATEMENTS OF OPERATIONS (Unaudited) (USD $)
 3 Months Ended
Mar. 31, 2014
Mar. 31, 2013
Revenue:    
Products, services, other $ 404,147 $ 221,569
Grant revenue    149,168
Total revenue 404,147 370,737
Costs and expenses:    
Cost of products, services and grants 177,606 104,544
Research and development 231,088 246,458
Selling and marketing 171,340 193,900
General and administrative 606,479 550,859
Total operating costs and expenses 1,186,513 1,095,761
Operating loss (782,366) (725,024)
Other (expense) income:    
Interest (expense) income,net (244,612) (8,900)
Change in fair value of warrant derivative liability (732,677) (45,445)
Total other (expense) income (977,289) (54,345)
Net loss (1,759,655) (779,369)
Accrued dividends on convertible preferred stock (44,987) (32,173)
Deemed dividend on convertible preferred stock (1,280,066) (582,548)
Net loss applicable to common shareholders $ (3,084,708) $ (1,394,090)
Net loss per share attributable to common stockholders - basic and diluted $ (0.25) $ (0.11)
Weighted average common stock shares outstanding used in the basic and diluted net loss per share calculation 12,122,045 12,149,267